Ariad And Merk Get Merry About Positive Phase III Data
- Wednesday, January 19, 2011, 3:31
- Market
- Add a comment
Ariad rockets higher after reporting results for its ridaforolimus drug to target soft tissue or bone tumors.
http://www.forbes.com/2011/01/18/todays-big-gainers-aria-hev-marketnewsvideo.html?feed=rss_markets
About the Author
admin123 has written 23412 stories on this site.
